share_log

HC Wainwright & Co. Reiterates Buy on Larimar Therapeutics, Maintains $15 Price Target

Benzinga ·  Dec 17 01:01  · Ratings

HC Wainwright & Co. analyst Edward White reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Buy and maintains $15 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment